Emergency department visits and hospitalizations for digoxin toxicity United States, 2005 to 2010

Circulation: Heart Failure

Volumn 7, Issue 1, 2014, Pages 28-34

  See, Isaac ^a,b   Shehab, Nadine ^a   Kegler, Scott R ^c   Laskar, S Raja ^d   Budnitz, Daniel S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Digoxin; Drug related side effects and adverse reactions; Emergency service, hospital; Heart failure; Hospitalization

Indexed keywords

DIGOXIN;

ADULT; AGED; ARTICLE; DIGITALIS INTOXICATION; DIGOXIN BLOOD LEVEL; DRUG SURVEILLANCE PROGRAM; EMERGENCY HEALTH SERVICE; EMERGENCY WARD; FEMALE; HEALTH SURVEY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; VERY ELDERLY;

DIGOXIN; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HOSPITALIZATION;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE; ANTI-ARRHYTHMIA AGENTS; DIGOXIN; DISEASE MANAGEMENT; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 84896121102     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.113.000784     Document Type: Article

References (41)

1. HCUPnet. Healthcare Cost and Utilization Product (HCUP). 2010. Agency for Healthcare Research and Quality. http://hcupnet.ahrq.gov. Accessed August 27, 2013.
2. Centers for Medicare and Medicaid Services. Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2013 rates; hospitals? resident caps for graduate medical education payment purposes; quality reporting requirements for specific providers and for ambulatory surgical centers. https://www.federalregister. gov/articles/2012/08/31/2012-19079/ medicare-program-hospital-inpatient- prospective-payment-systems-for-acute-care- hospitals-and-the. Accessed August 27, 2013.
3. Fiegl C. 2,200 hospitals face Medicare pay penalty for readmissions. American Medical News. http://www.ama-assn.org/amednews/2012/08/27/gvsb0827.htm. Accessed August 27, 2013.
4. Gheorghiade M, Harinstein ME, Filippatos GS. Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care. 2009;11:83-87.
5. Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS; CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-666.
6. Vivo RP, Krim SR, Perez J, Inklab M, Tenner T Jr, Hodgson J. Digoxin: current use and approach to toxicity. Am J Med. Sci. 2008;336:423-428.
7. Pervaiz MH, Dickinson MG, Yamani M. Is digoxin a drug of the past? Cleve Clin J Med. 2006;73:821-4, 826, 829.
8. Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol. 2012;109:1818-1821.
9. US Consumer Product Safety Commission. National Electronic Injury Surveillance System All Injury Program Sample Design and Implementation. Washington, DC: US Consumer Product Safety Commission; 2002.
10. Jhung MA, Budnitz DS, Mendelsohn AB, Weidenbach KN, Nelson TD, Pollock DA. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES). Med Care. 2007;45(10 Supl 2):S96-102.
11. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296:1858-1866.
12. Bousquet C, Lagier G, Lillo-Le Louët A, Le Beller C, Venot A, Jaulent MC. Appraisal of the MedDRA conceptual structure for describing and grouping adverse drug reactions. Drug Saf. 2005;28:19-34.
13. National Center for Health Statistics. NAMCS/NHAMCS questionnaires, datasets, and related documentation. http://www.cdc.gov/nchs/ahcd/ahcd- questionnaires.htm#public-use. Accessed August 27, 2013.
14. National Center for Health Statistics. Dataset documentation: National Ambulatory Medical Care. ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/Dataset- Documentation/NAMCS/. Accessed August 27, 2013.
15. National Center for Health Statistics. Dataset documentation: National Hospital Ambulatory Medical Care Survey. ftp://ftp.cdc.gov/pub/Health- Statistics/NCHS/Dataset-Documentation/NHAMCS/. Accessed August 27, 2013.
16. National Center for Health Statistics. Trend analysis using NAMCS and NHAMCS drug data. http://www.cdc.gov/nchs/ahcd/trend-analysis.htm. Accessed August 27, 2013.
17. National Center for Health Statistics. NAMCS/NHAMCS estimation procedures. http://www.cdc.gov/nchs/ahcd/ahcd-estimation-procedures. htm. Accessed August 27, 2013.
18. Kish L. Survey Sampling. New York: Wiley Interscience; 1995.
19. Kegler SR. Applying the compound Poisson process model to the reporting of injury-related mortality rates. Epidemiol Perspect Innov. 2007;4:1.
20. Top 200 Drugs of 1997. IMS analysis describes major market shifts. Pharmacy Times 1998; 64:31-49.
21. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336:525-533.
22. Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis? N Engl J Med. 1997;336:575-576.
23. Caccamo MA, Eckman PM. Pharmacologic therapy for New York Heart Association class IV heart failure. Congest Heart Fail. 2011;17:213-219.
24. Haynes K, Heitjan D, Kanetsky P, Hennessy S. Declining public health burden of digoxin toxicity from 1991 to 2004. Clin Pharmacol Ther. 2008;84:90-94.
25. Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG trial era. J Card Fail. 2006;12:343-346.
26. Adams KF Jr, Patterson JH, Gattis WA, O?Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. J Am Coll Cardiol. 2005;46:497-504.
27. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.
28. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002-2012.
29. Currie GM, Wheat JM, Kiat H. Pharmacokinetic considerations for digoxin in older people. Open Cardiovasc Med J. 2011;5:130-135.
30. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP. Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging. 2000;17:353-362.
31. Digitalis Investigation Group, Ahmed A, Waagstein F, Pitt B, White M, Zannad F, Young JB, Rahimtoola SH. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial. Am J Cardiol. 2009; 103:82-87.
32. Meyer P, White M, Mujib M, Nozza A, Love TE, Aban I, Young JB, Wehrmacher WH, Ahmed A. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure. Am J Cardiol. 2008;102:1681-1686.
33. Bourge RC, Fleg JL, Fonarow GC, Cleland JG, McMurray JJ, van Veldhuisen DJ, Gheorghiade M, Patel K, Aban IB, Allman RM, White- Williams C, White M, Filippatos GS, Anker SD, Ahmed A. Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med. 2013;126:701-708.
34. Gheorghiade M, Patel K, Filippatos G, Anker SD, van Veldhuisen DJ, Cleland JG, Metra M, Aban IB, Greene SJ, Adams KF, McMurray JJ, Ahmed A. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15:551-559.
35. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2013; 128:e240-e327.
36. Hauptman PJ, McCann P, Romero JM, Mayo M. Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Intern Med. 2013;173:1552-1554.
37. Haynes K, Hennessy S, Localio AR, Cohen A, Leonard CE, Kimmel SE, Feldman HI, Strom BL, Metlay JP. Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiol Drug Saf. 2009;18:28-35.
38. Bradley EH, Curry L, Horwitz LI, Sipsma H, Thompson JW, Elma M, Walsh MN, Krumholz HM. Contemporary evidence about hospital strategies for reducing 30-day readmissions: a national study. J Am Coll Cardiol. 2012;60:607-614.
39. Aarnoudse AL, Dieleman JP, Stricker BH. Age- and gender-specific incidence of hospitalisation for digoxin intoxication. Drug Saf. 2007;30:431-436.
40. Miura T, Kojima R, Sugiura Y, Mizutani M, Takatsu F, Suzuki Y. Effect of aging on the incidence of digoxin toxicity. Ann Pharmacother. 2000;34:427-432.
41. Francis GS. The contemporary use of digoxin for the treatment of heart failure. Circ Heart Fail. 2008;1:208-209.